Professional Timeline

2015

Published results of a study performed with colleagues at Lille University in France, of a new method for surgical treatment of abdominal wounds.

Presented a treatment result of a case of metastatic thymic cancer treated with novel combination therapy and leading to complete remission within months. Performed with colleagues from Excel Nuclear Oncology Center and presented at the Theranostics World Congress at Johns Hopkins University.

Appointed as Director of The Center for Drug Repurposing, Ariel University.

2014

Published research together with colleagues at Lille University, in France, identifying a novel marker as a diagnostic factor in Castleman’s Disease.

Published research together with colleagues at Lille University in France, concerning conservative surgical strategies for caustic gastric injuries.

2013

Published research together with colleagues from Lille University, in France, explaining the mechanism how gallium stops bleeding from wounds.

Granted FDA Orphan Drug Designation for the breakthrough energy-blocking drug 3-bromopyruvate for treating liver cancer.

Published research together with colleagues at Lille University in France, demonstrating sacral nerve stimulation as a new treatment for j-pouch related incontinence.

Granted FDA Orphan Drug Designation for the biological compound Opioid Growth Factor (OGF) for treating liver cancer.

2012

Published a comprehensive literature review of over 80 cases of patients treated with intravenous immunoglobulin for Crohn’s disease; with the intention of spearheading large trials of this safe novel treatment.

Published a comprehensive literature review in of all the anti-cancer effects of the Japanese anti-allergy drug Tranilast.

Published a seminal article in Investigational New Drugs, with researchers from Penn State University and Texas Children’s Hospital of a breakthrough treatment for the pediatric liver cancer, Hepatoblastoma, utilizing a novel biological therapy. The article describes two breakthrough cases, one 10 years and the other 6 years after being cured.

Published a book chapter, “Testosterone for the Treatment of Mammary and Prostate Cancers: Historical Perspectives and New Directions, Advances in Cancer Management,” describing the background and rationale for a novel treatment strategy for cancers of the breast and prostate cancer utilizing a combination of three hormonal drugs.

2011

Published a comprehensive review paper summarizing an additional nine clinical uses of the Japanese-approved Alopecia drug, Cepharanthine.

Published a case series demonstrating the effects of gallium salts in stopping bleeding from wounds.

2010

Published study in Anticancer Research, results showing that simple cough medication, noscapine, could be used as a preventive strategy for  occurrence of prostate . Research was performed with colleagues from Prostate Cancer Research Education Foundation, a 501(c)(3), non-profit organization in California and University of California at San Diego.

Published research with colleagues at Penn State University further elucidating popular skin cancer drug Aldara’s mechanism of action.

Completed literature research and summarization concerning Gout, sponsored by the Bulova Stetson Fund.

Launched LDNscience.org, the first scientific Low Dose Naltrexone portal serving close to 100,000 users annually.

2009

Filed patent application for breakthrough discovery for the use of Gallium, in stopping bleeding from wounds.

Delivered lecture at Israeli Government Ministry of Health about the off-label use of drugs in the treatment of cancer.

Arranged the first human treatment of liver cancer using the breakthrough energy blocking drug 3-bromopyruvate at University of Frankfurt, Germany. Case Study published in 2012.

Founded We Fund The Cure, a 501(c)(3), non-profit organization.

2008

Initiated a pediatric Crohn’s Disease study of Low Dose Naltrexone (LDN) at Hershey Medical Center, Penn State University with Dr. Jill Smith taking the lead.


Results of Imiquimod (Aldara) mechanism of action study published.


Published breakthrough research showing that a simple cough medication, noscapine, inhibits prostate cancer in mice. Work performed in collaboration with researchers from Prostate Cancer Research Education Foundation, a 501(c)(3), non-profit organization in California and University of California at San Diego.


Served in five Champions Oncology VIP Personalized Medicine Panels – leading to the cure (with 7 years follow-up) of 3 out 5 patients with stage IV cancers. Panel Details Follow.


Served as Panel Participant for Champions Oncology VIP World Expert Panel for Pancreatic Cancer chaired by Dr. David Sidransky of Johns Hopkins Medical Center.  Panel participants included:


Served as Panel Participant for Champions Oncology VIP World Expert Panel for Non-Small Cell Lung Cancer chaired by Dr. David Sidransky of Johns Hopkins Medical Center. Panel Participants included:


Served as Panel participant for Champions Oncology VIP World Expert Panel for Metastatic Melanoma chaired by Dr. David Sidransky of Johns Hopkins Medical Center. Panel Participants included:


Served as Panel participant for Champions Oncology VIP World Expert Panel for Sarcoma chaired by Dr. David Sidransky of Johns Hopkins Medical Center. Panel Participants included:


Served as Panel participant for Champions Oncology VIP World Expert Panel for Gastroesophageal Cancer chaired by Dr. David Sidransky of Johns Hopkins Medical Center. Panel Participants included:


Completed Research for the MedInsight® Diabetes Relief Project sponsored by the Myra Reinhard Foundation summarizing an average of 25 non-commercial pharmacological treatments each for Diabetic Nephropathy, Diabetic Neuropathy and Diabetic Retinopathy.

2007

Publication of Crohn’s Disease first clinical trial results with Low Dose Naltrexone (LDN) in American Journal of Gastroenterology

Published a white paper on simple cough medication, Noscapine’s usefulness in treating cancer and stroke in partnership with Prostate Cancer Research Education Foundation, a 501(c)(3) in La Mesa, California headed by Dr. Israel Barken.

2006

Patent Application filed for the use of Low Dose Naltrexone in treating Crohn’s Disease and Ulcerative Colitis. This patent was subsequently licensed to Immune Therapeutics Inc., a U.S. company then led by the late Dr. Ronald B. Herberman, founder and director of the University of Pittsburgh Cancer Institute.

Co-Founded MedInsight® Research Institute, a U.S. 501(c)(3) a non-profit Organization with Prof. David Youlton of the U.K., Chairman of the Digital Television Group.

2004

Initiated research at Penn State University with Dr. Ian Zagon and, Dr. Patricia McLaughlin to clarify the hitherto unknown mechanism of action of the widely used anti-skin-cancer drug Aldara. This breakthrough discovery was subsequently published in 2008 issue of Experimental Biology and Medicine.

2003

Published a white paper on simple cough medication, Noscapine’s usefulness in treating a number of cancers which led to adoption of its use as an anti-cancer drug by a number of private clinics worldwide.

2002

First ever clinical trial of Low Dose Naltrexone (LDN) initiated by Moshe Rogosnitzky at Penn State University, Hershey Medical Center; in collaboration with Dr. Ian Zagon, Dr. Patricia McLaughlin and Dr. Jill Smith.

This leads to a breakthrough in treating Crohn’s disease and spearheads the initiation of several clinical trials by others for the use of LDN in different autoimmune disorders. This has culminated in close to 10 clinical studies on this non-commercialized (i.e. non-pharmaceutical company sponsored) drug, with an estimated 300,000 patients worldwide using it on a daily basis to alleviate autoimmune and inflammatory diseases.